GUBBIOTTI, ALESSANDRO
GUBBIOTTI, ALESSANDRO
Mostra
records
Risultati 1 - 4 di 4 (tempo di esecuzione: 0.01 secondi).
Adalimumab biosimilars, ABP501 and SB5, are equally effective and safe as adalimumab originator
2021 Cingolani, L.; Barberio, B.; Zingone, F.; Ferronato, A.; Bertani, L.; Costa, F.; Bodini, G.; Demarzo, M. G.; Melatti, P.; Gubbiotti, A.; Massimi, D.; Casadei, C.; D'Inca, R.; Savarino, E. V.
Gastrointestinal: An unusual rectal finding in a patient with ulcerative colitis
2020 Barberio, B.; Gubbiotti, A.; Albertoni, L.; Ghisa, M.; Savarino, E.
Incidence comparison of adverse events in patients with inflammatory bowel disease receiving different biologic agents: retrospective long-term evaluation
2021 Barberio, Brigida; Savarino, Edoardo Vincenzo; Card, Timothy; Canova, Cristina; Baldisser, Francesco; Gubbiotti, Alessandro; Massimi, Davide; Ghisa, Matteo; Zingone, Fabiana
Infliximab Originator, Infliximab Biosimilar, and Adalimumab Are More Effective in Crohn's Disease Than Ulcerative Colitis: A Real-Life Cohort Study
2020 Barberio, B.; Zingone, F.; D'Inca, R.; Rovigo, L.; Bertani, L.; Bodini, G.; Ghisa, M.; Gubbiotti, A.; Massimi, D.; Lorenzon, G.; Savarino, E. V.